Welcome to our dedicated page for Vtv Therapeutics news (Ticker: VTVT), a resource for investors and traders seeking the latest updates and insights on Vtv Therapeutics stock.
vTv Therapeutics Inc. (Nasdaq: VTVT) is a late-stage biopharmaceutical company focused on oral, small molecule drug candidates for diabetes and other chronic diseases. News about VTVT frequently centers on the development of its lead program, cadisegliatin (TTP399), a novel liver-selective glucokinase activator being investigated as a potential first-in-class oral adjunctive treatment to insulin for people with type 1 diabetes.
Company updates often cover key milestones in the CATT1 Phase 3 trial of cadisegliatin in adults with type 1 diabetes, including trial initiation, randomization of the first study participant, and expectations for topline data. vTv Therapeutics also issues news on its Phase 2 clinical study protocol for cadisegliatin as an adjunctive therapy to insulin in people with type 2 diabetes, developed in collaboration with M42’s Insights Research Organization & Solutions (IROS) for sites in the United Arab Emirates, Jordan, and Tunisia.
Investors following VTVT news can expect regular clinical development updates, such as preclinical and clinical data presentations at scientific meetings, including the INNODIA Symposium at the European Association for the Study of Diabetes Annual Meeting. The company also reports on intellectual property developments, including U.S. patent allowances for crystalline forms of cadisegliatin with patent terms running through 2041.
Another recurring theme in vTv Therapeutics news is financing and corporate activity, such as private placements with healthcare institutional investors and the T1D Fund intended to support the CATT1 Phase 3 trial and broader cadisegliatin program. Updates on participation in investor conferences and changes to scientific advisory structures also appear in the news flow.
For readers tracking VTVT stock, this news page aggregates company press releases and related coverage so they can monitor progress in clinical trials, regulatory interactions, patent protection, and capital-raising efforts tied to vTv Therapeutics’ diabetes-focused pipeline.
Cantex Pharmaceuticals has received FDA Orphan Drug Designation for azeliragon to treat brain metastasis from breast cancer. This is the third such designation for azeliragon, following previous designations for pancreatic cancer and glioblastoma in mid-2024 and early 2023.
Azeliragon is an oral, once-daily compound that inhibits the RAGE receptor. The drug's interaction with RAGE on cancer cells has been linked to radiation resistance, disease progression, and metastasis development in breast cancer. This designation provides Cantex with seven years of marketing exclusivity upon product launch, along with development assistance, tax credits, and FDA fee exemptions.
vTv Therapeutics (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on novel small molecules and diabetes treatments, has announced its participation in the 7th Annual Evercore HealthCONx Conference in Coral Gables, Florida. The company's management will engage in a fireside chat and one-on-one meetings during the event, scheduled for December 3-5, 2024.
The presentation is set for December 4, 2024, from 7:55 to 8:15 AM ET. Interested parties can access a live webcast through the Events section of vTv's investor relations website. Meeting requests can be made through institutional contacts.
vTv Therapeutics (Nasdaq: VTVT) announced its 2024 third quarter financial results and provided a corporate update. The company reported a cash position of $41.6 million as of September 30, 2024, up from $9.4 million at the end of 2023, largely due to private placement financing and ATM Offering proceeds. R&D expenses rose to $3.2 million from $2.8 million due to higher indirect costs, offset by lower spending on cadisegliatin. G&A expenses increased to $3.3 million from $2.5 million, driven by higher share-based, legal, and payroll costs. The net loss attributable to shareholders was $4.8 million or $0.88 per share, down from $6.7 million or $3.19 per share a year ago. The company’s lead program, cadisegliatin, is under FDA clinical hold, but discussions are ongoing. Total assets were $43.2 million, and total liabilities were $25.3 million as of September 30, 2024.
vTv Therapeutics (Nasdaq: VTVT) reported Q2 2024 financial results and provided a corporate update. Key highlights include:
- Screened first patient in cadisegliatin pivotal trial for type 1 diabetes (T1D), currently on clinical hold
- Expanded Newsoara Biopharma license agreement for PDE4 inhibitor HPP737 to a global license for $20 million upfront
- Azeliragon received Orphan Drug Designation for pancreatic cancer
- Q2 2024 financial results: Cash position of $45.5 million, R&D expenses of $3.4 million, G&A expenses of $3.7 million
- Net loss of $5.2 million or $0.81 per basic share
The company is working to resolve the clinical hold on cadisegliatin and resume the study as quickly as possible.
vTv Therapeutics Inc. (Nasdaq: VTVT) announced that the FDA has placed a clinical hold on its cadisegliatin program for type 1 diabetes, including the ongoing CATT1 Phase 3 trial. The hold is due to an unresolved chromatographic signal discovered in a recent human ADME study. The FDA requires an in vitro study to characterize this signal before the program can resume.
Key points:
- No patients had been dosed in CATT1 at the time of the hold
- Past clinical studies showed no concerning safety issues
- Cadisegliatin has been well-tolerated in over 500 subjects for up to six months
- The company is working to resolve the hold and resume enrollment quickly
vTv Therapeutics has initiated the first patient screening for its CATT1 pivotal trial, evaluating cadisegliatin as an adjunct treatment for type 1 diabetes (T1D). Cadisegliatin is a first-in-class oral liver-selective glucokinase activator, designed to regulate blood glucose levels by selectively activating liver glucose pathways. The FDA has granted it Breakthrough Therapy designation for T1D.
The trial will enroll approximately 150 patients across 20 U.S. sites. Cadisegliatin will be tested against a placebo in patients using insulin injections and continuous glucose monitors. The primary endpoint is to compare the incidence of Level 2 or Level 3 hypoglycemic events. Future Phase 2 trials for type 2 diabetes (T2D) are planned in the Middle East.
Cantex Pharmaceuticals announced that four abstracts featuring azeliragon, a RAGE inhibitor, will be presented at the 2024 ASCO Annual Meeting in Chicago. Azeliragon, a once-a-day pill, is being investigated for its potential in treating various difficult-to-treat cancers. The abstracts cover studies on azeliragon's safety and therapeutic effects in metastatic pancreatic cancer, its use in combination with temozolomide and radiotherapy for newly diagnosed glioblastoma, its role in reducing cardiotoxicity in women with early breast cancer, and its effectiveness when combined with stereotactic radiation therapy in patients with brain metastases. The meeting provides a platform for showcasing clinical progress to leading oncology researchers globally.
Cantex Pharmaceuticals announced that the FDA has granted Orphan Drug Designation to its drug azeliragon for treating pancreatic cancer. This designation follows a similar status received for treating glioblastoma in 2023. The designation offers benefits like seven years of marketing exclusivity, tax credits, and fee exemptions. Cantex is conducting a clinical trial to study azeliragon's efficacy on metastatic pancreatic cancer patients in top U.S. cancer centers. CEO Stephen G. Marcus emphasized the urgent need for new treatments for advanced pancreatic cancer and other cancers, enhancing their commitment to innovative therapies.
vTv Therapeutics Inc. reported its 2024 first-quarter financial results, showcasing significant milestones and corporate updates. The company's cash position grew to $52.3 million, thanks to a successful private placement, funding future Phase 3 studies for cadisegliatin. The submission of the Phase 3 trial protocol to the FDA marks a pivotal step towards developing adjunctive therapy for type 1 diabetes. Financially, R&D expenses decreased, while G&A expenses increased slightly. The company reported a net loss of $4.9 million for the quarter.
Summary not available.